1. Home
  2. CRSP vs TNL Comparison

CRSP vs TNL Comparison

Compare CRSP & TNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$51.20

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Logo Travel   Leisure Co.

TNL

Travel Leisure Co.

HOLD

Current Price

$74.74

Market Cap

4.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
TNL
Founded
2013
1990
Country
Switzerland
United States
Employees
393
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.7B
IPO Year
2016
2006

Fundamental Metrics

Financial Performance
Metric
CRSP
TNL
Price
$51.20
$74.74
Analyst Decision
Buy
Buy
Analyst Count
17
7
Target Price
$70.29
$84.00
AVG Volume (30 Days)
1.6M
566.0K
Earning Date
05-11-2026
04-22-2026
Dividend Yield
N/A
3.80%
EPS Growth
N/A
N/A
EPS
N/A
1.22
Revenue
$289,590,000.00
$4,021,000,000.00
Revenue This Year
$807.72
$3.56
Revenue Next Year
$172.52
$3.55
P/E Ratio
N/A
$60.29
Revenue Growth
9169.85
4.06
52 Week Low
$44.12
$55.92
52 Week High
$78.48
$81.00

Technical Indicators

Market Signals
Indicator
CRSP
TNL
Relative Strength Index (RSI) 42.57 53.52
Support Level $47.92 $70.79
Resistance Level $59.61 $78.03
Average True Range (ATR) 3.39 1.88
MACD -0.83 -0.54
Stochastic Oscillator 12.78 47.37

Price Performance

Historical Comparison
CRSP
TNL

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About TNL Travel Leisure Co.

Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.

Share on Social Networks: